



## **Pevonedistat hydrochloride**

**Catalog No: tcsc0068** 

Available Sizes
Size: 1mg
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Size: 200mg
Specifications
CAS No: 1160295-21-5
Formula: C <sub>21</sub> H <sub>26</sub> CIN <sub>5</sub> O <sub>4</sub> S
Pathway: Metabolic Enzyme/Protease
Target: NEDD8-activating Enzyme
Purity / Grade: >98%
<b>Solubility:</b> DMSO : ≥ 160 mg/mL (333.35 mM)
Alternative Names: MLN4924 (hydrochloride)





## **Observed Molecular Weight:**

479.98

## **Product Description**

Pevonedistat hydrochloride (MLN4924 hydrochloride) is a potent and selective NEDD8-activating enzyme (**NAE**) inhibitor, with an **IC** 50 of 4.7 nM.

IC50 & Target: IC50: 4.7 nM (NAE)

In Vitro: Pevonedistat (MLN4924) is a potent inhibitor of NAE (half-maximal inhibitory concentration (IC $_{50}$ =0.004  $\mu$ M), and is selective relative to the closely related enzymes UAE, SAE, UBA6 and ATG7 (IC $_{50}$ =1.5, 8.2, 1.8 and >10  $\mu$ M, respectively). Pevonedistat (MLN4924) treatment inhibits overall protein turnover in cultured HCT-116 cells. Treatment of HCT-116 cells with Pevonedistat (MLN4924) for 24 h results in a dose-dependent decrease of Ubc12-NEDD8 thioester and NEDD8-cullin conjugates, with an IC $_{50}$ [1]. Pevonedistat induces CLL cell apoptosis and circumvented stroma-mediated resistance. Pevonedistat promotes induction of Bim and Noxa in the CLL cells leading to rebalancing of Bcl-2 family members toward the proapoptotic BH3-only proteins<sup>[2]</sup>. Pevonedistat (MLN4924) rapidly inhibits cullin 1 neddylation and remarkably suppressed growth and survival as well as migration in a dose-and time-dependent manner in gastric cancer cells, and significantly suppresses migration by transcriptionally activating E-cadherin and repressing MMP-9<sup>[3]</sup>.

*In Vivo:* Pevonedistat (MLN492410, 30 or 60 mg/kg, s.c.) leads to a dose- and time-dependent increase in the steady state levels of NRF2 and CDT1 in HCT-116 tumour-bearing mice, and decreases NEDD8-cullin levels in normal mouse tissue as illustrated in mouse bone marrow cells. Pevonedistat (MLN4924) administered on a BID schedule at 30 and 60 mg/kg inhibits tumour growth with T/C values of 0.36 and 0.15, respectively<sup>[1]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!